A new class of selective oral drugs overstressing pathological cells to cure patients
BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy with a first focus on treating cancers patients
Our Technology
See the Science Behind Our Treatment
Science & Technology
First-in-class selective BiP inhibitors to treat cancers and beyond
BPR001-615 is first-in-class, highly selective, orally bioavailable, targeted therapy designed to treat the > 50% of BiP High patients through a precision medicine approach across multiple indications
Know moreAbout
About BiPER Therapeutics
BiPER ‘s name summarizes the original and unique approach of our Lead candidate targeting BiP and leading to cancer cell death through unresolved ER (Endoplasmic Reticulum) Stress induction
BIPER Therapeutics primary focus is to treat cancer patients by pushing cancer cells to burn out. We are advancing a first pipeline of first-in-class small molecules that induce unresolved ER stress in cancer cells and strentengh non-cancer cells to change the course of disease and change patients' life
Patients Supported in Care
Investors & Partnership
Partner with Innovation
BiPER Therapeutics seeks collaboration with pharmaceutical leaders and investors to accelerate the clinical development of our first-in-class BiP inhibitors and redefine the standard of care.
Collaborating with premier scientific pioneers to define the next generation of cancer care
Contact
Get in Touch
Whether you are an investor, potential partner, or researcher, reach out to explore how we can collaborate to bring these life-saving therapies to patients.